DE:3AC Stock Latest News
Company AnnouncementsActinogen boosts cash to $21.9m after ATO R&D rebate1w ago
Company AnnouncementsActinogen locks Alzheimer’s trial database, eyes mid-November Xanamem readout1w ago
Company AnnouncementsActinogen Medical Announces Employee Share Scheme Buy-Back3w ago
Company AnnouncementsActinogen Sets AGM as Pivotal Alzheimer’s Trial Nears Key Readout3w ago
Company AnnouncementsActinogen Medical Adds Modest Number of New Shares to ASX Listing1M ago
Company AnnouncementsActinogen issues underwritten shortfall shares as Xanamem trials advance1M ago
Company AnnouncementsActinogen extends cash runway to 2028 after completing option underwriting1M ago
Company AnnouncementsActinogen Completes Visits in Pivotal Alzheimer’s Trial Ahead of November Data1M ago- Company AnnouncementsActinogen Medical Options Expire, Streamlining ASX-Listed Capital Structure1M ago
Company AnnouncementsActinogen Medical Seeks ASX Quotation for 21.9 Million New Shares1M ago
Company AnnouncementsActinogen Medical Seeks ASX Quotation for 22.5 Million New Shares1M ago
Company AnnouncementsActinogen Director Boosts Shareholding Through Option Exercise1M ago
Company AnnouncementsActinogen Showcases Cortisol-Targeting Alzheimer’s Drug Ahead of Key Trial Readout1M ago
Company AnnouncementsActinogen Medical Seeks ASX Quotation for 8 Million New Shares1M ago
Company AnnouncementsActinogen Medical Expands ASX-Quoted Share Capital1M ago- Company AnnouncementsActinogen Medical Seeks ASX Quotation for 11.9 Million New Shares2M ago
- Company AnnouncementsActinogen Plans Major Share Placement to Bolster Funding Capacity2M ago
Company AnnouncementsActinogen secures full underwriting of $4.77m options to extend Xanamem funding runway2M ago